1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Dong-E-E-Jiao Co., Ltd. Class A

Dong-E-E-Jiao Co., Ltd. Class A

SSZSE:000423
46.96
CNY
+0.02
(+0.04%)
29.02BMarket Cap
Mar 22Next Earn
Dong-E-E-Jiao Co., Ltd. Class A
SZSE:000423
(Shenzhen Stock Exchange)

Recent

price

46.96

P/E

ratio

- -

div

yld

0.00%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
3.77
4.22
4.67
6.14
6.13
8.33
9.66
11.27
11.23
4.57
5.51
5.94
6.27
7.33
9.57
10.4
- -
Revenue per Share
0.89
1.31
1.59
1.84
2.09
2.48
2.83
3.13
3.19
-0.7
0.07
0.68
1.21
1.79
2.42
2.7
- -
Basic EPS, GAAP
0.76
0.74
0.88
0.61
0.58
1.06
0.42
2.21
1.16
-2.24
1.13
4.29
3.26
2.95
4.28
3.43
- -
Free Cash Flow per Basic Share
0.33
0.3
0.33
0.7
0.7
0.8
0.81
0.94
0.95
1.1
0.24
0.3
0.65
1.18
3
2.54
- -
Dividend per Share
4.19
5.24
6.49
7.65
9.06
10.72
12.78
15.05
17.28
15.26
14.88
15.25
15.79
16.65
16.02
16.05
15.88
Book Value per Share
4
5.01
6.26
7.37
8.7
10.41
12.49
14.54
16.62
14.59
14.2
14.62
15.28
16.14
15.54
15.52
15.26
Tangible Book Value per Share
654
654
654
654
654
654
654
654
654
650
618
648
645
643
643
644
641
Basic Weighted Avg Shares
2,464
2,759
3,056
4,016
4,009
5,450
6,317
7,372
7,338
2,970
3,409
3,849
4,042
4,715
6,157
6,700
- -
Sales/Revenue/Turnover
26.09
34.53
36.03
33.12
36.32
32.23
32.44
31.7
32.29
-14.63
15.06
21.7
21.49
26.07
26.8
29.34
- -
Operating Margin (%)
48
47
55
56
74
94
103
106
114
141
153
162
167
162
153
153
- -
Depreciation Expense
582
856
1,040
1,203
1,366
1,625
1,852
2,044
2,085
-455
43
440
780
1,151
1,557
1,739
- -
Net Income, GAAP
15.25
16.02
15.35
15.12
14.94
15.02
15.53
15.12
14.62
- -
75.27
23.14
14.56
15.48
16.1
15.6
- -
Effective Tax Rate (%)
23.63
31.03
34.04
29.95
34.06
29.82
29.32
27.73
28.41
-15.31
1.27
11.44
19.3
24.41
25.29
25.95
- -
Profit Margin (%)
1,783
2,595
3,237
3,205
4,070
4,978
6,092
7,199
8,302
6,597
6,725
7,188
7,683
8,130
7,697
7,692
7,269
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
37
48
42
31
22
39
47
LT Debt
2,817
3,475
4,311
5,084
6,028
7,083
8,386
9,872
11,329
10,029
9,775
9,995
10,351
10,741
10,338
10,363
10,230
Total Equity
21.5
26.58
25.86
25.07
24.11
24.43
23.12
21.83
18.75
- -
0.39
4.52
7.79
11.08
14.94
16.97
- -
Return on Invested Capital (%)
21.58
26.77
26.38
25.31
24.47
24.48
23.85
22.63
19.91
- -
0.5
4.49
7.67
10.88
14.77
16.77
- -
Return on Capital (%)
22.65
27.77
27.12
26.01
25
25.12
24.1
22.46
19.72
-4.27
0.44
4.47
7.68
10.94
14.81
16.84
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
21
21
35
LT Borrowings
- -
- -
- -
LT Finance Leases
39
44
47
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
644
644
640
Market Capitalization
31,606
36,816
29,023

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
10,552
10,711
9,575
Cash, Cash Equivalents & STI
9,083
9,130
7,978
Accounts Receivable, Net
132
507
589
Inventories
836
936
897
Total Current Liabilities
2,859
2,548
2,306
Payables & Accruals
- -
- -
- -
ST Debt
21
21
35
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.29%
1.22%
0.25%
Free Cash Flow
16.81%
57.79%
-19.86%
Net Income, GAAP
88.4%
217.81%
11.66%
Sales/Revenue/Turnover
6.14%
14.79%
8.83%
Total Cash Common Dividend
32.05%
73.31%
-15.35%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,453
1,295
1,581
1,592
6,157
2025
1,719
1,332
- -
1,934
6,700
2026
1,814
1,341
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.55
0.6
0.64
0.63
2.42
2025
0.66
0.61
- -
0.73
2.7
2026
0.71
0.63
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
1.15
- -
3
2025
- -
- -
- -
- -
2.54
2026
- -
- -
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Dong-E-E-Jiao Co., Ltd. (000423.SZ) is a China-based company principally engaged in the research, development, production and sales of donkey-hide gelatin (Ejiao) and related traditional Chinese medicines; headquartered in Liaocheng, Shandong Province, and founded in 1952, it operates as a subsidiary of China Resources Pharmaceutical Group Limited, which holds an effective controlling stake of approximately 23.5%; the company manufactures and markets a comprehensive portfolio of over 100 products across six major categories, including Ejiao in forms such as blocks, Compound Ejiao Paste, Peach Blossom Princess Ejiao Cake, Ejiao instant powder, Royal Paddock 1619, Zhuangben Ejiao minced meat puree and Yan Zhenqing Ejiao bird's nest; additional offerings encompass Chinese patent medicines, health foods, foods, bio-medicines, pharmaceutic adjuvants and medical equipment, with the Dong-E branded Ejiao accounting for about 75% of national production and 90% of exports; products target domestic markets in eastern, southern, southwestern and northern China, as well as international customers in Southeast Asia, Europe and the United States. The company maintains advanced facilities including a national Ejiao traditional Chinese medicine engineering technology research center and a postdoctoral workstation, supporting over 300 patents and participation in national standards formulation; it employs around 4,000 staff and focuses on high-tech innovation as a national innovative enterprise. Recent developments include the launch in late 2024 of three desert ginseng (Cistanche deserticola) products under the Zhuangben brand—a concentrate, a tonic drink blended with donkey-hide gelatin, and a prebiotic paste—marking expansion into men's health, anti-aging and foods-as-medicines segments via a new subsidiary in Inner Mongolia's Alxa League; in 2025, the company revised its restricted stock incentive plan, adjusting the assessment period to 2025-2027 with elevated performance targets such as return on equity of at least 11.5-12.5%; it also deepened strategic partnerships, including with Shandong Sports Bureau, Shandong Radio and Television Station and Tencent Video for sports and health initiatives, and earned recognitions like 2025 Phoenix Star Most Socially Responsible Listed Company and a spot on the BrandZ Most Valuable Chinese Brands ranking; further, plans advance to acquire 80% of Inner Mongolia Alxa Cistanche Group and 70% of Dongfeng Majie Pharmaceutical to bolster supplement projects, while H1 2025 net profit rose 10.7-11% year-over-year amid ongoing R&D investments.